Avelumab, Palbociclib and Axitinib in Advanced RCC
Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to see whether the combination of 3 drugs (axitinib, avelumab and
palbociclib) is safe and effective in slowing down the growth of advanced clear cell renal
cell carcinoma (ccRCC) in patients that have not received any prior systemic treatment.
The names of the study drug involved in this study are/is:
- Axitinib
- Avelumab
- Palbociclib